Charles Schwab Investment Management Inc. Has $6.93 Million Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

Charles Schwab Investment Management Inc. raised its stake in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 209.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 844,617 shares of the company's stock after acquiring an additional 571,345 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.68% of Wave Life Sciences worth $6,926,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Emerald Advisers LLC bought a new stake in shares of Wave Life Sciences during the second quarter worth $12,441,000. Emerald Mutual Fund Advisers Trust bought a new stake in Wave Life Sciences during the 2nd quarter worth about $9,086,000. Vanguard Group Inc. lifted its position in Wave Life Sciences by 39.7% during the 1st quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company's stock valued at $11,316,000 after purchasing an additional 521,665 shares during the period. Driehaus Capital Management LLC lifted its position in Wave Life Sciences by 62.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company's stock valued at $4,531,000 after purchasing an additional 348,300 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Wave Life Sciences in the 2nd quarter valued at about $668,000. 89.73% of the stock is owned by institutional investors.

Insider Buying and Selling at Wave Life Sciences

In related news, CFO Kyle Moran sold 17,146 shares of Wave Life Sciences stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $9.00, for a total transaction of $154,314.00. Following the completion of the sale, the chief financial officer now directly owns 19,777 shares of the company's stock, valued at approximately $177,993. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Chris Francis sold 208,836 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $13.67, for a total value of $2,854,788.12. The disclosure for this sale can be found here. Insiders sold 453,690 shares of company stock valued at $6,425,883 in the last quarter. 29.10% of the stock is currently owned by insiders.

Wave Life Sciences Trading Down 10.1 %

Shares of WVE traded down $1.56 during mid-day trading on Thursday, reaching $13.85. The company's stock had a trading volume of 1,755,652 shares, compared to its average volume of 1,107,269. Wave Life Sciences Ltd. has a 1-year low of $3.50 and a 1-year high of $16.74. The business has a 50-day simple moving average of $13.70 and a two-hundred day simple moving average of $8.67. The stock has a market cap of $2.11 billion, a P/E ratio of -12.48 and a beta of -1.21.

Analyst Ratings Changes

A number of research firms recently weighed in on WVE. Leerink Partners boosted their price target on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Mizuho upped their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Wells Fargo & Company raised their price target on Wave Life Sciences from $11.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 16th. StockNews.com downgraded Wave Life Sciences from a "hold" rating to a "sell" rating in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $22.22.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.